Tuesday, Ascendis Pharma A/S (NASDAQ:ASND) reported second-quarter sales of $38.76 million (35.9 million euros), missing the consensus of $92.7 million, down from 47.4 million euros reported a year ...

To date, every court that has considered substantive challenges to the Medicare drug price negotiation program has ruled ...

Pharma's investment in the digital health space is getting more and more real and substantive as companies move beyond the pilot stage and start to launch real digital health interventions, from Teva ...

The pharmaceutical supply chain operates on a global and fragile network. Many active pharmaceutical ingredients (APIs) and ...

Over the past decade, pharma has made digital health a strategic priority, launching patient apps, HCP platforms, adherence tools, and data-driven services. Yet, outcomes remain mixed. Many ...

A federal appeals court in Philadelphia rejected challenges by some of New Jersey’s biggest pharmaceutical companies questioning the legality of the federal government requiring drug makers to ...

Once the active ingredient is defined, an Applicant must select which patent, or patents, to put forward for extension. The statute permits only one PTE per regulatory review period, so the choice is ...

A pharmaceutical company is currently appealing a record USD1.6 billion judgment in the US, arguing that a key part of the US False Claims Act (FCA) is unconstitutional. This case, now before the ...

The daily schedules of healthcare professionals (HCPs) are busy, leaving little time to spend searching for information on medicines. Like all areas of modern life, HCPs are turning to online ...

Cantor Fitzgerald writes that the Skytrofa update probably overshadowed another key update from the call. Achieving breakeven this year is unlikely unless the company significantly reduces costs, ...